"Increasing levels of the RNA-binding protein tristetraprolin (TTP) in elderly mice reduced frailty and improved bone health."
Turning Back the Clock on Frailty
Researchers at the University at Buffalo have discovered that boosting a specific protein in elderly mice can reverse key signs of aging, including frailty, muscle weakness, and bone deterioration.
Published in the January 2026 issue of Aging and Disease, the study was supported by a $2.1 million NIH grant. The protein in question is tristetraprolin (TTP), an RNA-binding molecule that naturally declines in the body with age.
TTP plays a critical role in controlling inflammation by breaking down inflammatory signals. As TTP levels drop, chronic inflammation rises—a hallmark of aging.
The Science in Action
Genetically modified mice aged 22 months—elderly for a mouse—with stabilized TTP showed remarkable improvements:
- Lower frailty scores compared to their unmodified peers
- Better grip strength, walking speed, and treadmill endurance
- Healthier bones with reduced bone breakdown
- More youthful immune profiles, suggesting a systemic anti-aging effect
Interestingly, male mice showed greater improvements than females. Researchers believe this may be due to their smaller body size and the natural decline of estrogen in older females, which complicates the aging process.
What’s Next?
The research team plans to explore TTP's potential to reduce neuroinflammation in dementia and Alzheimer's disease, where chronic inflammation in the brain is a major driver of cognitive decline.
However, early efforts to find drugs that increase TTP expression have not yet been successful. The team is actively screening compounds but has not identified a viable candidate.
A Note of Caution
Lead author Keith Kirkwood (University at Buffalo) emphasized that human treatments are still far off. These findings are preliminary and based strictly on mouse models.
"Further research is needed before any applications to human health can be considered."
While the results are promising, the path from rodent studies to human therapies is long, and significant hurdles remain.